Discovery and characterization of novel inhibitors of the sodium-coupled citrate transporter (NaCT or SLC13A5)-Reference-Cited by-同舟云学术

Discovery and characterization of novel inhibitors of the sodium-coupled citrate transporter (NaCT or SLC13A5)

Published:2015-12 Issue:1 Volume:5 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Huard Kim,Brown Janice,Jones Jessica C.,Cabral Shawn,Futatsugi Kentaro,Gorgoglione Matthew,Lanba Adhiraj,Vera Nicholas B.,Zhu Yimin,Yan Qingyun,Zhou Yingjiang,Vernochet Cecile,Riccardi Keith,Wolford Angela,Pirman David,Niosi Mark,Aspnes Gary,Herr Michael,Genung Nathan E.,Magee Thomas V.,Uccello Daniel P.,Loria Paula,Di Li,Gosset James R.,Hepworth David,Rolph Timothy,Pfefferkorn Jeffrey A.,Erion Derek M.

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/srep17391.pdf

Reference44 articles.

1. Magnusson, I., Rothman, D. L., Katz, L. D., Shulman, R. G. & Shulman, G. I. Increased rate of gluconeogenesis in type II diabetes mellitus a 13C nuclear magnetic resonance study. J. Clin. Invest. 90, 1323–1327 (1992).

2. Browning, J. D. et al. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology 40, 1387–1395, 10.1002/hep.20466 (2004).

3. Eckel, R. H., Grundy, S. M. & Zimmet, P. Z. The metabolic syndrome. Lancet 365, 1415–1428, 10.1016/S0140-6736(05)66378-7 (2005).

4. McCullough, A. J. Pathophysiology of nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 40, S17–S29, 10.1097/01.mcg.0000168645.86658.22 (2006).

5. Inzucchi, S. E. et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. New Engl. J. Med. 338, 867–872, 10.1056/NEJM199803263381303 (1998).

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Plasma membrane transporter Progressive Ankylosis Protein Homolog (ANKH/Ankh) mediates senescence-derived extracellular citrate and is regulated by DNA damage, inflammation and ageing;2024-08-30

2. Discovery of Highly Potent Solute Carrier 13 Member 5 (SLC13A5) Inhibitors for the Treatment of Hyperlipidemia;Journal of Medicinal Chemistry;2024-04-04

3. Metabolic basis of solute carrier transporters in treatment of type 2 diabetes mellitus;Acta Pharmaceutica Sinica B;2024-02

4. Novel Approaches to Studying SLC13A5 Disease;Metabolites;2024-01-24

5. The growing research toolbox for SLC13A5 citrate transporter disorder: a rare disease with animal models, cell lines, an ongoing Natural History Study and an engaged patient advocacy organization;Therapeutic Advances in Rare Disease;2024-01